

## Special Issue

# Immunocyto/Histochemistry in the Era of Immunotherapy

### Message from the Guest Editors

Immunotherapy in oncology is a breakthrough in the treatment of cancer. Treatment of cancer with immune checkpoint inhibitors (ICI) capable of unleashing T cells to exponentially expand and kill transformed cells, is the most recent and appealing treatment strategy being developed in the last decade. ICIs have been improving the survival of cancer patients. Nevertheless, not all patients respond and some of them show severe autoimmune toxicities and only 20–30% of treated patients present long term benefits. It is compelling to validate predictive and prognostic biomarkers to identify patients who are most likely to benefit from immunotherapy upfront and those who need to integrate/combine the immune-treatment with other strategies that can synergize the otherwise useless immunotherapy treatment. While some predictive factors of response to ICIs have been proposed, including PD-L1 expression, high tumor mutational burden, and mismatch repair gene defects, reliable biomarkers for the resistance to treatment are still lacking. This is in part due to the complexity of the tumor immune microenvironment and its impact on the immune drug efficacy.

---

### Guest Editors

Dr. Ilaria Grazia Zizzari


Dr. Ilary Ruscito

Prof. Dr. A. Rughetti

---

### Deadline for manuscript submissions

closed (30 September 2021)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/52589](https://mdpi.com/si/52589)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).